Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

SpringWorks Therapeutics (SWTX) had Revenue of $49.09M for the most recently reported fiscal quarter, ending 2025-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-03-31

Income Statement Financials
Revenue	$49.09M
Net Income	$-83.19M
Cost of Goods Sold	$3.53M
Gross Profit	$45.56M
Operating Expenses	$129.62M
Operating Income	$-80.54M
Non-Operating Income/Expense	$-2.65M
Pre-Tax Income	$-83.19M
Normalized Pre-Tax Income	$-83.19M
Income after Taxes	$-83.19M
Income from Continuous Operations	$-83.19M
Consolidated Net Income/Loss	$-83.19M
Normalized Income after Taxes	$-83.19M
EBIT	$-80.54M
EBITDA	$-79.44M
Weighted-Average Shares Outstanding (Basic)	74.89M
Weighted-Average Shares Outstanding (Diluted)	74.89M
Earnings per Share (EPS) (Basic)	$-1.11
Earnings per Share (EPS) (Diluted)	$-1.11
Balance Sheet Financials
Current Assets	$356.32M
Property, Plant, and Equipment	$19.25M
Long-Term Assets	$149.04M
Total Assets	$505.36M
Current Liabilities	$82.27M
Long-Term Debt	--
Long-Term Liabilities	$5.69M
Total Liabilities	$87.96M
Common Equity	$417.39M
Tangible Shareholders Equity	$417.39M
Shareholders Equity	$417.39M
Common Shares Outstanding	74.99M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-68.76M
Cash Flow from Investing Activities	$73.39M
Cash Flow from Financial Activities	$-10.61M
Beginning Cash	$70.38M
End Cash	$64.40M
Increase/Decrease in Cash	$-5.97M
Stock-Based Compensation	$29.95M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.33
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	--
Debt to Equity Ratio	--
Gross Margin	92.81%
Operating Margin	-164.07%
EBIT Margin	-164.07%
EBITDA Margin	--
Pre-Tax Profit Margin	-169.47%
Profit Margin	-169.47%
Free Cash Flow	$-68.79M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.10
Inventory Turnover	0.28
Receiveable Turnover	1.22
Days Sales in Receivables	73.98
Return on Equity	-19.93%
Return on Tangible Equity	-19.93%
Return on Assets	-16.46%
Return on Investments	-19.93%
Book Value Per Share	$5.57
Free Cash Flow per Share	$-0.92
Operating Cash Flow per Share	$-0.92

Data from Zacks Investment Research, Inc.